drugset / Trial / NCT04802083
COVID-19 Soliris Expanded Access Protocol
Summary
This protocol provides participants with COVID-19 access to Soliris.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eculizumab | Monoclonal antibody | 900 mg | Intravenous |
| Subject | Eculizumab | Monoclonal antibody | 1200 mg | Intravenous |